$3.92▴ 4.39%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
$-43.84MTTM operating cash
Pre-profit
It is still burning cash while pre-profit.
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
+65.7%year over year
Strong
Revenue is growing strongly year over year.
Leverage
Moderatedebt to assets
Watch
Elevated leverage worth keeping an eye on.
More coming: dilution / share-count creep.
✦ The read
Aquestive Therapeutics, Inc. is pre-profit. It is still burning cash while pre-profit. Revenue is growing strongly year over year. Elevated leverage worth keeping an eye on.
Key numbers
Valuation
EPS (TTM)$-0.62
TTM (trailing 12 months, through fiscal Q1 FY2026)
Profitability
Net margin-137.1%
TTM (trailing 12 months, through fiscal Q1 FY2026)
Size
Revenue (TTM)$50.27M
TTM (trailing 12 months, through fiscal Q1 FY2026)
Signals and key numbers are from the fiscal Q1 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.